The Maryland Prescription Drug Affordability Board (PDAB) was established in April 2019 as the first in the US to address high drug prices[1][4]. The board consists of five members plus a Stakeholder Council and reviews high-cost drugs that pose an affordability challenge in healthcare, including for patients[2][5]. By December 2020, it was to review the drug distribution system and recommend a funding source[1]. Starting in 2022, the PDAB may set upper payment limits (UPLs) for drugs purchased by state and local governments[2][3]. In 2025, the board proposed UPLs for the drugs Jardiance (for heart) and Farxiga (for type 2 diabetes and kidney), both identified as unaffordable[3][4]. Governor Wes Moore approved an expansion of the PDAB's authority to apply limits to private plans for all Maryland residents beginning in 2026[3][4]. The PDAB serves as a model for other states in addressing the drug pricing crisis[4].